Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02586909 · ClinicalTrials.gov registry record · Phase 3
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Phase 3 study, sponsored by Axovant Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,099
- Enrollment target
NCT02586909 is a Phase 3 study that was terminated before completion, run by Axovant Sciences. The registered enrollment target is 1,099 participants.
The verdict
NCT02586909, a Phase 3 study, was terminated before completion, sponsored by Axovant Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,099 participants
- Enrollment target
Study Summary
This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind, placebo-controlled, lead-in study RVT-101-3001 (double-blind study).
Interventions
- DRUG RVT-101 35 mg tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,099 participants |
| Start Date | 2016-04-26 |
| Est. Completion | 2018-03-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02586909
The ClinicalTrials.gov registry entry for NCT02586909 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,099 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axovant Sciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RVT-101 35 mg tablets is the first listed.
NCT02586909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02586909 about?
NCT02586909 is a clinical study titled "12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension". This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind, placebo-controlled, lead-in study RVT-101-3001 (double-blind study).
What is the current status of trial NCT02586909?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,099 participants. The study started on 2016-04-26. Estimated completion is 2018-03-12.
What interventions are being tested in trial NCT02586909?
The interventions under investigation include: RVT-101 35 mg tablets (DRUG).
Who is sponsoring clinical trial NCT02586909?
This trial is sponsored by Axovant Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.